发布求助
文献互助 智能选刊 最新文献

Recenti progressi in medicina最新文献

筛选
英文 中文
In questo numero
2024 Ottobre. 本期内容2024 年 10 月
Recenti progressi in medicina Pub Date : 2024-10-01 DOI: 10.1701/4357.43458
{"title":"In questo numero<br>2024 Ottobre.","authors":"","doi":"10.1701/4357.43458","DOIUrl":"https://doi.org/10.1701/4357.43458","url":null,"abstract":"","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 10","pages":"435"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142506799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Primary care delivered non-pharmacologic preventive interventions improve function and quality of life but do not decrease the likelihood of hospitalization or need for residential long-term care in older adults.] [初级保健提供的非药物预防性干预可改善老年人的功能和生活质量，但并不能降低老年人住院的可能性或对长期住院护理的需求。］
Recenti progressi in medicina Pub Date : 2024-10-01 DOI: 10.1701/4357.43465
Peter K Kurotschka, Henry Barry, Alice Serafini
{"title":"[Primary care delivered non-pharmacologic preventive interventions improve function and quality of life but do not decrease the likelihood of hospitalization or need for residential long-term care in older adults.]","authors":"Peter K Kurotschka, Henry Barry, Alice Serafini","doi":"10.1701/4357.43465","DOIUrl":"https://doi.org/10.1701/4357.43465","url":null,"abstract":"","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 10","pages":"475-476"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142506790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Opioid use during pregnancy is not associated with an increased risk of neuropsychiatric disorders in children.] [妊娠期使用阿片类药物与儿童神经精神障碍的风险增加无关]。
Recenti progressi in medicina Pub Date : 2024-10-01 DOI: 10.1701/4357.43468
Alice Serafini, Allen Shaughnessy, Peter K Kurotschka
{"title":"[Opioid use during pregnancy is not associated with an increased risk of neuropsychiatric disorders in children.]","authors":"Alice Serafini, Allen Shaughnessy, Peter K Kurotschka","doi":"10.1701/4357.43468","DOIUrl":"https://doi.org/10.1701/4357.43468","url":null,"abstract":"","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 10","pages":"481-482"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142506789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Levonorgestrel-releasing intrauetrine devices, compared to no hormonal contraception, are associated with a reduced risk of ischemic stroke and equal risk of intracerebral hemorrhage.] [左炔诺孕酮释放型宫内节育器与不使用激素避孕相比，缺血性中风的风险降低，脑内出血的风险相同。］
Recenti progressi in medicina Pub Date : 2024-10-01 DOI: 10.1701/4357.43467
Peter K Kurotschka, Henry Barry, Alice Serafini
{"title":"[Levonorgestrel-releasing intrauetrine devices, compared to no hormonal contraception, are associated with a reduced risk of ischemic stroke and equal risk of intracerebral hemorrhage.]","authors":"Peter K Kurotschka, Henry Barry, Alice Serafini","doi":"10.1701/4357.43467","DOIUrl":"https://doi.org/10.1701/4357.43467","url":null,"abstract":"","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 10","pages":"479-480"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142506786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
L’utilizzo di sacituzumab govitecan in linea avanzata di malattia in paziente anziana con tumore della mammella metastatico divenuto triplo negativo. 在患有三阴性转移性乳腺癌的老年患者的晚期疾病中使用sacituzumab govitecan。
Recenti progressi in medicina Pub Date : 2024-10-01 DOI: 10.1701/4357.43483
Cinzia Cardalesi
{"title":"L’utilizzo di sacituzumab govitecan in linea avanzata di malattia in paziente anziana con tumore della mammella metastatico divenuto triplo negativo.","authors":"Cinzia Cardalesi","doi":"10.1701/4357.43483","DOIUrl":"10.1701/4357.43483","url":null,"abstract":"<p><p>Triple-negative breast carcinoma is known for its aggressive profile and the lack of hormonal or HER2 therapeutic targets. This subtype of tumor is particularly challenging to treat, especially in elderly patients, where tolerance to standard therapeutic regimens may be reduced and multiple comorbidities further complicate clinical management. In this scenario, sacituzumab govitecan (SG) is revolutionizing the therapeutic pathway by offering a particularly active treatment, especially in advanced forms resistant to conventional therapies, with a manageable toxicity profile and reassuring data on efficacy even in case of dose reductions. In this clinical case, we describe the use of SG in a 71-year-old patient diagnosed with metastatic breast cancer histologically shifted from luminal B to triple negative, who had already received numerous and varied hormonal and chemotherapeutic treatment lines. Despite the need for dose reduction due to G3 diarrhea, after 16 months of therapy, the patient continues treatment with minimal impact on quality of life and maintaining stability after a partial response of the disease.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 10","pages":"68e-71e"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142506800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Medical practices in places of culture and intense architecture: how the visit experience changes.] [文化场所和密集建筑中的医疗实践：就诊体验如何变化]。
Recenti progressi in medicina Pub Date : 2024-10-01 DOI: 10.1701/4357.43462
Eleonora Gerbotto, Guido Giustetto, Raffaella Lecchi, Luca Mo Costabella
{"title":"[Medical practices in places of culture and intense architecture: how the visit experience changes.]","authors":"Eleonora Gerbotto, Guido Giustetto, Raffaella Lecchi, Luca Mo Costabella","doi":"10.1701/4357.43462","DOIUrl":"https://doi.org/10.1701/4357.43462","url":null,"abstract":"<p><p>Cultura di Base is an experimental project realised in Torino between May and October 2022. Some General Practitioners' offices were moved to cultural places of the city, such as museums, libraries, cultural centers, with recognised quality in terms of space design and architecture. The assumption to be tested is that \"intense architecture offices\" can improve the experience of the visit and possibly strengthen the relationship between patient and doctor. Our counterfactual impact evaluation, based on a quasi-experimental control group design, evidences a significant positive impact both on the perceptions of waiting time and on the post-visit psychological well-being.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 10","pages":"447-454"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142506788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Long term survival in patient with metastatic breast cancer treated with sacituzmab govitecan.] [转移性乳腺癌患者接受sacituzmab govitecan治疗后的长期生存率]
Recenti progressi in medicina Pub Date : 2024-10-01 DOI: 10.1701/4357.43484
Carlo Mulas, Luigi Mascia
{"title":"[Long term survival in patient with metastatic breast cancer treated with sacituzmab govitecan.]","authors":"Carlo Mulas, Luigi Mascia","doi":"10.1701/4357.43484","DOIUrl":"https://doi.org/10.1701/4357.43484","url":null,"abstract":"<p><p>The clinical case presented refers to a woman suffering from metastatic breast cancer treated with sacituzumab govitecan (SG) who has a long progression-free survival. The case is characterized by the extreme aggressiveness of the neoplastic disease that relapses during adjuvant hormonal treatment with a metastatic disease that presents immunohistochemical characteristics different from the primary tumor. After first-line therapy with nabpaclitaxel and atezolizumab and the subsequent one with carboplatin and gemcitabine, both characterized by short PFS, the third line with SG is characterized by obtaining a complete response and a prolonged PFS as well as extreme tolerability that continues to this day after 15 months of treatment.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 10","pages":"72e-76e"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142506787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dalla letteratura
2024 Ottobre. 摘自文献 2024 年 10 月。
Recenti progressi in medicina Pub Date : 2024-10-01 DOI: 10.1701/4357.43459
{"title":"Dalla letteratura<br>2024 Ottobre.","authors":"","doi":"10.1701/4357.43459","DOIUrl":"https://doi.org/10.1701/4357.43459","url":null,"abstract":"","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 10","pages":"437-439"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142506798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Intra-patient cancer heterogeneity and sacituzumab-govitecan efficacy.] [患者内部癌症异质性与Sacituzumab-Govitecan疗效]
Recenti progressi in medicina Pub Date : 2024-10-01 DOI: 10.1701/4357.43480
Andrea Fontana, Federica Pantaleo
{"title":"[Intra-patient cancer heterogeneity and sacituzumab-govitecan efficacy.]","authors":"Andrea Fontana, Federica Pantaleo","doi":"10.1701/4357.43480","DOIUrl":"https://doi.org/10.1701/4357.43480","url":null,"abstract":"<p><p>Advanced triple negative breast cancer (TNBC) represents a challenging clinical condition with limited therapeutics opportunities. However, recently, a new antibody drug conjugated, sacituzumab govitecan, demonstrated a relevant clinical efficacy in this setting of patients. In this report we describe the case of a patient with TNBC diagnosed at the metastatic level when the primary breast tumour presented overexpression of ER end PgR. An important tumoral heterogeneity has been described in breast cancer during its natural evolution and for that reason is important to perform metastatic lesions re-biopsy, when feasible, in order to re-evaluate the biological characteristics and define the optimal therapeutic strategy.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 10","pages":"57e-60e"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142506785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinical management of a patient with non-triple-negative breast cancer who converts to a triple-negative subtype at recurrence.] [非三阴性乳腺癌患者在复发时转变为三阴性亚型的临床治疗]。
Recenti progressi in medicina Pub Date : 2024-10-01 DOI: 10.1701/4357.43481
Francesca Poggio
{"title":"[Clinical management of a patient with non-triple-negative breast cancer who converts to a triple-negative subtype at recurrence.]","authors":"Francesca Poggio","doi":"10.1701/4357.43481","DOIUrl":"https://doi.org/10.1701/4357.43481","url":null,"abstract":"<p><p>The management of patients with advanced breast cancer is becoming increasingly complex compared to the past, mainly due to numerous therapeutic innovations introduced in the current therapeutic scenario. At the time of metastatic disease diagnosis, as indicated by the guidelines, it is important to perform a biopsy of the metastatic sites to optimize choices and expand therapeutic options. Approximately 25-45% of patients who experience a recurrence of the primary tumor lose hormone receptor expression: in this context, solid data comes from a subanalysis of the randomized clinical trial ASCENT, in which the benefit of a treatment with antibody-drug conjugate sacituzumab govitecan is also confirmed in case of non-triple negative breast cancer at diagnosis that subsequently convert to a triple negative subtype. The case reported below is representative of this clinical situation.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 10","pages":"61e-64e"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142506779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信